S&T BIOMED CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
At the current stage, the primary focus is on developing oral cancer biomarker in vitro diagnostic reagent products, while also successively developing related precision screening technologies and products for major diseases such as pancreatic cancer and COVID-19. Striving towards product realization, the ultimate goal is to achieve "preventive medicine" and precision medicine.
The content above was translated by Ai
Founded Year
2016
Unified Business No.
66387476
Status
Active
Number of Employees
0
Total Paid-in
Capital
146,730,090 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
In December 2016, S&T BIOMED CO., LTD. was established by three founders, including Chairman Hung-Ta Chiu. S&T BIOMED CO., LTD. is a technology-oriented company that continuously accumulates capabilities by integrating the technologies of top medical and industrial teams throughout Taiwan through industry-academia technology transfers. S&T BIOMED CO., LTD. has always adhered to the mission of providing simple, rapid, and accurate testing for cancer and performing effective disease management through its non-invasive biomarker detection service platform. Currently, the products launched on the market for clinical application are two "oral cancer in vitro diagnostic reagent" products, and commercial development is successively underway for major cancers such as pancreatic cancer, colorectal cancer, gastric cancer, and biliary tract cancer. The company hopes to provide simple, rapid, and accurate testing for cancer and achieve effective disease management through its non-invasive biomarker detection service platform, thereby striving for the greatest well-being of the health of our nation's people and humanity worldwide.
The content above was translated by Ai
